8-Bromo-cGMP (sodium)

8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca2+ macroscopic currents and impairs insulin release stimulated with high K+[1]. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses[2].

Product Specifications

CAS Number

[51116-01-9]

UNSPSC

12352005

Target

Calcium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/8-bromo-cgmp-sodium.html

Purity

99.89

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

O=C1C2=C(N([C@H]3[C@H](O)[C@@](OP(OC4)(O[Na])=O)([H])[C@]4([H])O3)C(Br)=N2)NC(N)=N1

Molecular Formula

C10H10BrN5NaO7P

Molecular Weight

446.08

References & Citations

[1]Sarkar O , et al. Nitric oxide attenuates overexpression of Giα proteins in vascular smooth muscle cells from SHR: Role of ROS and ROS-mediated signaling. PLoS One. 2017 Jul 10;12 (7) :e0179301.|[2]Tegeder I , et al. Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci Lett. 2002 Oct 31;332 (2) :146-50.|[3]Tobias Polte, et al. Atrial natriuretic peptide reduces cyclosporin toxicity in renal cells: role of cGMP and heme oxygenase-1. Free Radic Biol Med. 2002 Jan 1;32 (1) :56-63.|[4]Junzo Kamei, et al. Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in mice. Pain. 2005 Sep;117 (1-2) :112-20.|[5]Elza D van Deel, et al. Vasomotor control in mice overexpressing human endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2007 Aug;293 (2) :H1144-53.